Abattis Bioceuticals Corp. (ATTBF)

[guay]

Abattis Agrees to License Its NOXX Botanical Blends Products
VANCOUVER, BC / ACCESSWIRE / April 6, 2016 / Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) ("Abattis') has agreed to enter a licensing arrangement and marketing partnership with Crimson Capital Group ("Crimson") to commercialize Abattis' NÖXX Botanical Blends Products, which contain Abattis' patent-pending Phyto(NOS)™.

Abattis and Crimson plan to enter into an exclusive licensing agreement within thirty days, subject to all necessary approvals. "We are extremely excited to be commercializing our NÖXX Botanical Blends Products", says Brazos Minshew, Abattis' Director and Master Formulator. "We have an array of innovative products and Crimson is well positioned to implement critical elements of our marketing, sales and distribution strategy. Abattis considered building these capabilities internally and funding the efforts ourselves, but ultimately elected to secure this valuable partnership with trusted and capable industry professionals."

Under the Agreement with Abattis, Crimson will be responsible for funding and staffing the proposed commercialization efforts. Abattis and Crimson have agreed to enter into a licensing arrangement and to form a marketing partnership wherein Crimson will secure initial capital commitments of up to $1 million. Abattis will have the option of earning 50% of the profits from the partnership in consideration for common shares issuable to Crimson, or simply to earn a cash royalty of 2.5% on product sales. Abattis' board of directors have conditionally approved the terms of the Agreement and it is presently being submitted for review by the Canadian Stock Exchange (the "CSE").

For further information, contact the Company at [phone] or at [e-mail].

http://finance.yahoo.com/news/abattis-agrees-license-noxx-botanical-145600249.html